About AphioTx
AphioTx is a company based in Calgary (Canada) founded in 2021 by Roger Thompson. AphioTx operates in a competitive market with competitors including Indivior, Ethypharm, IgGenix, Braeburn and Cessation Therapeutics, among others.
- Headquarter Calgary, Canada
- Founders Roger Thompson
- SectorsHealthcare
- Email••••••••
- Website aphiotx.com
- Social LinkedIn X
People of AphioTx
1 people are tracked at AphioTx (1 in leadership).
| Name | Role | Group |
|---|---|---|
Roger Thompson | Co-Founder | Leadership |
Complete people profiles for AphioTx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Competitors of AphioTx
AphioTx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Indivior, Ethypharm, IgGenix, Braeburn and Cessation Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| indivior.com | 2014 | Richmond Hill, United States | – | 1,051 | Therapeutics for opioid addiction treatment are developed and commercialized. | |
| ethypharm.com | 1977 | Saint Cloud, France | $248.09M | – | Therapies for pain and addiction treatment are developed. | |
| iggenix.com | 2019 | San Francisco, United States | $75M | – | Therapeutic solutions for food allergies are developed via antibody platforms. | |
| braeburnrx.com | 2012 | Philadelphia, United States | $110M | – | Long-acting therapies for opioid addiction and chronic pain are developed. | |
| cessationtherapeutics.com | 2017 | San Jose, United States | $6.76M | – | Developer of immunotherapy based vaccines to manage addictions | |
| amygns.com | 2015 | San Francisco, United States | $7.05M | – | Therapies for substance use disorders are developed by Amygdala Neurosciences. | |
| aelisfarma.com | 2013 | Bordeaux, France | $14.04M | – | Developer of small molecule drugs targeting CB1 receptor for CNS diseases | |
| titanpharm.com | 1992 | San Francisco, United States | – | 11 | A specialty pharmaceutical company developing proprietary therapeutics for select chronic diseases | |
| 4p-pharma.com | 2014 | Lille, France | $18.49M | – | French Biotech startup that develops to clinical trial stage the molecules it has in-licensed | |
| biotie.com | 1998 | Turku, Finland | $149.81M | 27 | Drugs for neurodegenerative and psychiatric disorders are developed by Biotie. |
Detailed competitors of AphioTx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to AphioTx
10 companies that operate in the same segment as AphioTx (Toxicology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutic solutions for food allergies are developed via antibody platforms. | 2019 | San Francisco, California, United States | USD 75 M | – | – | |
Therapeutics for substance use disorders, including opioid-related conditions, are developed. | 2020 | Oakland, California, United States | USD 70 M | – | – | |
Drug delivery solutions via single-walled carbon nanotubes are offered. | 2008 | Houston, Texas, United States | USD 2.5 M | USD 5.07 M | 9 | |
Non-invasive drug testing technology is developed using fingerprints. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 25.71 M | – | – | |
Provides toxicology, chemistry, and consultancy services for agrochemical industries. | 2020 | Vapi, Gujarat, India | – | – | – | |
Instruments for rapid human DNA identification are developed. | 2006 | Pleasanton, California, United States | USD 92.06 M | USD 22.5 B | 78 | |
Oral therapies for snake bite treatment are developed. | 2015 | Corte Madera, California, United States | USD 16.48 M | – | – | |
Quantitative urine drug testing is provided for patient monitoring. | 2011 | San Diego, California, United States | – | – | 358 | |
Point-of-care platforms for heavy metal toxicity diagnostics are developed. | 1968 | Billerica, Massachusetts, United States | USD 34 M | – | – | |
Real-time trace gas analysis solutions are delivered using SIFT-MS technology. | 2002 | Christchurch, New Zealand | USD 11.9 M | USD 23.52 M | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about AphioTx
AphioTx was founded in 2021.
AphioTx is headquartered in Calgary, Canada. It is registered at Calgary, Alberta, Canada.
AphioTx was founded in 2021 in Calgary, Canada, within the biotechnology sector. Small molecule and protein-based biotherapeutics are developed to address opioid use disorder. The pannexin-1 protein is targeted by these treatments, which close the associated channel. Opioid withdrawal symptoms, chronic pain, and cognitive impairment are alleviated through this mechanism. Operations focus on therapeutic innovation for addiction and related conditions, led by co-founder Roger Thompson.